Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Apr 18;7(Suppl 1):102–109. doi: 10.1111/jdi.12490

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Wide use of dipeptidyl peptidase‐4 inhibitors (DPP‐4i) as a first choice therapy in Japan. (a) The number of individuals receiving DPP‐4i among those treated with oral antidiabetic drugs (OAD). Those treated with insulin and/or glucagon‐like peptide‐1 are not included. Note that more than 70% of individuals with OAD receive DPP‐4i in Japan today. (b) Profiles of antidiabetic drug use before initiating DPP‐4i. Note that approximately 60% of individuals receive DPP‐4i as a first choice therapy in Japan. Data were derived from the Japan Medical Data Centre Claims Database (Japan Medical Data Centre Co., Ltd, Tokyo, Japan), which contains the following information on individuals aged <75 years in employment‐based health insurance programs: age and sex of patient; diagnosis of disease using International Classification of Diseases‐10 code; and prescribed drugs. Reproduced from Yabe et al.29 with permission.